Quick Answer
Janux Therapeutics, Inc. reported R&D Expense of $125.90 million for fiscal year 2025.
Janux Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $125.90M | +84.1% |
| 2024 | $68.39M | +24.5% |
| 2023 | $54.92M | +2.8% |
| 2022 | $53.44M | +103.7% |
| 2021 | $26.24M | +762.8% |
| 2020 | $3.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $34.63M | +86.0% | -0.1% |
| June 30, 2025 | $34.66M | +132.7% | +38.4% |
| March 31, 2025 | $25.05M | +78.1% | +34.6% |
| September 30, 2024 | $18.61M | +56.5% | +24.9% |
| June 30, 2024 | $14.90M | -0.2% | +5.9% |
| March 31, 2024 | $14.07M | -11.3% | +18.3% |
| September 30, 2023 | $11.89M | -13.4% | -20.3% |
| June 30, 2023 | $14.92M | +5.9% | -5.9% |
- Janux Therapeutics, Inc. showed an increase of +84.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Janux Therapeutics, Inc.’s r&d expense has grown by 4040.0% (from $3.04 million to $125.90 million).
- The most recent figure is from Janux Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: